ArticleThoracic cancer2021
Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer.
Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Longitudinal PET/CT-Derived Body Composition Changes During Systemic Therapy in Patients with Lung Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Strategies to mitigate muscle mass loss in individuals with spinal cord injury.The journal of spinal cord medicine · 2026Review
- Advancing sarcopenia assessment with wearable and app-based technology: a scoping review.The journal of nutrition, health & aging · 2026Article
- Short-Term Biceps Muscle Wasting Assessed by Serial Ultrasound as a Predictor of Survival Duration in Terminally Ill Cancer Patients: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Does pre-checkpoint inhibitor sarcopenia, visceral, or subcutaneous fat predict survival in non-small cell lung cancer patients?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Early adipose tissue wasting in a preclinical model of human lung cancer cachexia.Cell reports · 2025Article
- A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.Cancers · 2025Review
- Body composition alterations in patients with lung cancer.American journal of physiology. Cell physiology · 2025Review
- Diversity in chemotherapy-induced cachexia.American journal of physiology. Cell physiology · 2025Review
- Skeletal muscle adaptations in patients with lung cancer: Longitudinal observations from the whole body to cellular level.Journal of cachexia, sarcopenia and muscle · 2023Article
- Call for standardization in assessment and reporting of muscle and adipose change using computed tomography analysis in oncology: A scoping review.Journal of cachexia, sarcopenia and muscle · 2023Article
- Skeletal muscle index is associated with long term outcomes after lobectomy for non-small cell lung cancer.BMC cancer · 2023Article
- Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis.World journal of clinical cases · 2022Article
- Cancer, Phase Angle and Sarcopenia: The Role of Diet in Connection with Lung Cancer Prognosis.Lung · 2022Review
- Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles.Frontiers in pharmacology · 2022Review
- Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer.Thoracic cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSkeletal muscle depletion (sarcopenia) is associated with poor prognosis in patients with lung cancer. We analyzed changes in skeletal muscle area using serial computed tomography (CT) until the death of patients with advanced squamous cell lung cancer (SQCLC).
methodsThis retrospective study comprised 70 consecutive patients who underwent palliative chemotherapy for SQCLC. The cross-sectional area of the skeletal muscle at the level of the first lumbar vertebra (L1) was measured using chest CT. An artificial intelligence algorithm was developed and used for the serial assessment of the muscle area. Sarcopenia was defined as an L1 skeletal muscle index <46 cm
resultsThe median age was 69 years; 62 patients (89%) had metastatic disease at the time of initial diagnosis. Sarcopenia was present in 58 patients (82.9%) at baseline; all patients experienced net muscle loss over the disease trajectory. The median overall survival was 8.7 (95% confidence interval 5.9-11.5) months. The mean percentage loss of skeletal muscle between the first and last CT was 16.5 ± 11.0%. Skeletal muscle loss accelerated over time and was the highest in the last 3 months of life (p < 0.001). Patients losing skeletal muscle rapidly (upper tertile, >3.24 cm
conclusionsPatients with advanced SQCLC lose a significant amount of skeletal muscle until death. The rate of muscle area reduction is faster at the end of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.